• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生存素和连接黏附分子4表达在乳腺癌预后中的意义

The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma.

作者信息

Athanassiadou Anna Maria, Patsouris Efstratios, Tsipis Angelos, Gonidi Maria, Athanassiadou Pauline

机构信息

1st Pathology Laboratory, Cytology Unit, Medical School, University of Athens, Athens, Greece.

出版信息

Folia Histochem Cytobiol. 2011;49(1):26-33. doi: 10.5603/fhc.2011.0005.

DOI:10.5603/fhc.2011.0005
PMID:21526486
Abstract

To investigate the prognostic significance of Survivin and Nectin-4 expression in breast carcinomas. Imprint smears were obtained from 140 breast carcinoma specimens and studied immunocytochemically for the expression of Survivin and Nectin-4. The results were correlated with several clinicopathological parameters, including five-year survival. Increased Survivin staining pattern correlated with increased grade (p < 0.0001), increased lymph node invasion (p < 0.0001), increased tumor size and reduced survival (p < 0.0001). Elevated Nectin-4 expression also correlated significantly with increased grade (p < 0.0001), increased tumor size (p < 0.0001) and reduced survival (p < 0.0001). In addition, Survivin and Nectin-4 staining patterns correlated strongly with one another (p < 0.0001). However, on multivariate analysis, neither Survivin nor Nectin-4 expression seemed to have an independent impact on survival in our study cases. The findings of our study suggest that increased expression of Survivin and Nectin-4 may indicate a worse prognosis in breast cancer patients. The exact implications of the expression of these markers in breast cancer prognosis and treatment remain to be clarified.

摘要

探讨生存素(Survivin)和连接黏附分子4(Nectin-4)在乳腺癌中的表达及其预后意义。从140例乳腺癌标本中获取印片涂片,采用免疫细胞化学方法研究Survivin和Nectin-4的表达情况。将结果与包括五年生存率在内的多项临床病理参数进行相关性分析。Survivin染色增强与肿瘤分级增加(p<0.0001)、淋巴结转移增加(p<0.0001)、肿瘤大小增加及生存率降低(p<0.0001)相关。Nectin-4表达升高也与肿瘤分级增加(p<0.0001)、肿瘤大小增加(p<0.0001)及生存率降低(p<0.0001)显著相关。此外,Survivin和Nectin-4染色模式之间存在强相关性(p<0.0001)。然而,在多因素分析中,在我们的研究病例中,Survivin和Nectin-4的表达似乎均对生存无独立影响。我们的研究结果表明,Survivin和Nectin-4表达增加可能提示乳腺癌患者预后较差。这些标志物在乳腺癌预后和治疗中的具体意义仍有待阐明。

相似文献

1
The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma.生存素和连接黏附分子4表达在乳腺癌预后中的意义
Folia Histochem Cytobiol. 2011;49(1):26-33. doi: 10.5603/fhc.2011.0005.
2
High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.高生存素mRNA表达是乳腺癌预后不良的一个预测指标:一项mRNA和蛋白质水平的比较研究。
Breast Cancer. 2014 Jul;21(4):482-90. doi: 10.1007/s12282-012-0403-9. Epub 2012 Sep 12.
3
Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer.Nectin-4表达在腔面B型(HER2阴性)乳腺癌中的预后作用。
Pathol Res Pract. 2017 Sep;213(9):1102-1108. doi: 10.1016/j.prp.2017.07.019. Epub 2017 Jul 24.
4
The prognostic significance of COX-2 and survivin expression in ovarian cancer.COX-2和生存素表达在卵巢癌中的预后意义。
Pathol Res Pract. 2008;204(4):241-9. doi: 10.1016/j.prp.2007.11.004. Epub 2008 Jan 2.
5
Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast.KAI1和survivin表达在乳腺浸润性导管癌中的预后价值
Pathology. 2005 Apr;37(2):131-6. doi: 10.1080/00313020500058144.
6
Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma.Survivin 表达与乳腺导管癌临床形态学参数及激素受体状态的相关性。
Neoplasma. 2012;59(1):30-7. doi: 10.4149/neo_2012_004.
7
Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.LAPTM4B、VEGF和生存素水平升高与乳腺癌患者的肿瘤进展及不良预后相关。
Oncotarget. 2017 Jun 20;8(25):41282-41293. doi: 10.18632/oncotarget.17176.
8
Survivin expression and serum levels in pancreatic cancer.胰腺癌中Survivin的表达及血清水平
World J Surg Oncol. 2015 May 28;13:189. doi: 10.1186/s12957-015-0605-7.
9
Expression of survivin and clinical correlation in patients with breast cancer.乳腺癌患者中生存素的表达及其临床相关性
Biomed Pharmacother. 2006 Jul;60(6):289-92. doi: 10.1016/j.biopha.2006.06.008. Epub 2006 Jun 23.
10
Survivin in breast lesions: immunohistochemical analysis of 196 cases.乳腺病变中的生存素:196例免疫组织化学分析
Pol J Pathol. 2017;68(4):297-305. doi: 10.5114/pjp.2017.73925.

引用本文的文献

1
Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects.乳腺癌中Nectin-4的靶向治疗策略:最新进展与未来展望
Breast. 2025 Feb;79:103838. doi: 10.1016/j.breast.2024.103838. Epub 2024 Nov 14.
2
The prognostic role of survivin expression in breast cancer: A systematic review and meta-analysis. survivin 在乳腺癌中的预后作用:系统评价和荟萃分析。
Medicine (Baltimore). 2024 Oct 4;103(40):e40013. doi: 10.1097/MD.0000000000040013.
3
Joint multi-omics discriminant analysis with consistent representation learning using PANDA.
使用PANDA进行具有一致表示学习的联合多组学判别分析。
Res Sq. 2024 May 17:rs.3.rs-4353037. doi: 10.21203/rs.3.rs-4353037/v1.
4
Therapeutic prospects of nectin-4 in cancer: applications and value.Nectin-4在癌症治疗中的前景:应用与价值
Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389/fonc.2024.1354543. eCollection 2024.
5
Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS.PVRL4 的表达,一种癌症治疗的分子靶标,受 FOS 的转录调控。
Oncol Rep. 2024 Jan;51(1). doi: 10.3892/or.2023.8676. Epub 2023 Dec 8.
6
Cell Fusion and Syncytia Formation in Cancer.癌细胞的融合与合胞体形成。
Results Probl Cell Differ. 2024;71:433-465. doi: 10.1007/978-3-031-37936-9_20.
7
Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.抗体药物偶联物在膀胱癌中的应用:现状与展望。
Curr Treat Options Oncol. 2023 Sep;24(9):1167-1182. doi: 10.1007/s11864-023-01114-y. Epub 2023 Jul 5.
8
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.9MW2821 的临床前评价,一种基于单甲基澳瑞他汀 E 的定点偶联抗体药物,用于治疗 nectin-4 表达的癌症。
Mol Cancer Ther. 2023 Aug 1;22(8):913-925. doi: 10.1158/1535-7163.MCT-22-0743.
9
Prognostic value of nectin-4 in human cancers: A meta-analysis.Nectin-4在人类癌症中的预后价值:一项荟萃分析。
Front Oncol. 2023 Mar 3;13:1081655. doi: 10.3389/fonc.2023.1081655. eCollection 2023.
10
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.BT8009;一种针对 nectin-4 的衔接子毒素偶联物,用于治疗实体瘤。
Mol Cancer Ther. 2022 Dec 2;21(12):1747-1756. doi: 10.1158/1535-7163.MCT-21-0875.